Bastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, Marcel J R Janssen, Steffie M B Peters, Willemijn A M van Gemert, Maike J M Uijen, Melline M G Schilham, J P Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O Barentsz, Winald R Gerritsen, J Alfred Witjes, James Nagarajah
{"title":"177Lu-PSMA在低体积激素敏感性前列腺癌中的试点研究更新。","authors":"Bastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, Marcel J R Janssen, Steffie M B Peters, Willemijn A M van Gemert, Maike J M Uijen, Melline M G Schilham, J P Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O Barentsz, Winald R Gerritsen, J Alfred Witjes, James Nagarajah","doi":"10.3389/fnume.2022.863101","DOIUrl":null,"url":null,"abstract":"<p><p><sup>177</sup>Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of <sup>177</sup>Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, <sup>177</sup>Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.</p>","PeriodicalId":81537,"journal":{"name":"International family planning perspectives","volume":"18 1","pages":"863101"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440840/pdf/","citationCount":"0","resultStr":"{\"title\":\"An Update to the Pilot Study of <sup>177</sup>Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer.\",\"authors\":\"Bastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, Marcel J R Janssen, Steffie M B Peters, Willemijn A M van Gemert, Maike J M Uijen, Melline M G Schilham, J P Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O Barentsz, Winald R Gerritsen, J Alfred Witjes, James Nagarajah\",\"doi\":\"10.3389/fnume.2022.863101\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><sup>177</sup>Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of <sup>177</sup>Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, <sup>177</sup>Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.</p>\",\"PeriodicalId\":81537,\"journal\":{\"name\":\"International family planning perspectives\",\"volume\":\"18 1\",\"pages\":\"863101\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440840/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International family planning perspectives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fnume.2022.863101\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International family planning perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2022.863101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer.
177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
